{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T13:11:01Z","timestamp":1795093861581,"version":"4.10.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.vaccine.2024.01.100","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T07:26:56Z","timestamp":1707722816000},"page":"2200-2211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":210,"title":["COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals"],"prefix":"10.1016","volume":"42","author":[{"given":"K.","family":"Faksova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Naus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Escolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pillsbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.Z.","family":"Janjua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Per\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nasreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Artama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Clothier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Paynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Petousis-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hviid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.100_b0005","unstructured":"World Health Organization. WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed October 13, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0010","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations - Our World in Data 2023. https:\/\/ourworldindata.org\/covid-vaccinations (accessed October 13, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0015","unstructured":"Safety Platform for Emerging Vaccines S. D2.3 Priority list of adverse events of special interest: COVID-19. Brighton Collaboration; 2020. Available from: https:\/\/zenodo.org\/records\/6656179#.Y-0yxuyZOnN."},{"key":"10.1016\/j.vaccine.2024.01.100_b0020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/pds.5610","article-title":"Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting","volume":"32","author":"van der Boom","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.100_b0025","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.100_b0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/10543406.2015.1052819","article-title":"Evaluating efficiency and statistical power of self-controlled case series and self-controlled risk interval designs in vaccine safety","volume":"26","author":"Li","year":"2016","journal-title":"J Biopharm Stat"},{"key":"10.1016\/j.vaccine.2024.01.100_b0035","article-title":"Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study","volume":"373","author":"Potteg\u00e5rd","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.100_b0040","unstructured":"European Medicines Agency. Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])-Vaxzevria (previously COVID-19 Vaccine AstraZeneca) (Other viral vaccines). 2021."},{"key":"10.1016\/j.vaccine.2024.01.100_b0045","unstructured":"Global Vaccine Data Network. Observed vs. expected analyses of COVID-19 vaccine adverse events of special interest study protocol. Version 1.4. Auckland (NZ): Global Vaccine Data Network; 2022. Available from: https:\/\/www.globalvaccinedatanetwork.org\/sites\/globalvaccinedatanetwork.org\/files\/2024-01\/GVDN-observed-vs.-expected-analyses-of-COVID-19-vaccine-AESI-V1.4.pdf."},{"key":"10.1016\/j.vaccine.2024.01.100_b0050","unstructured":"Global Vaccine Data Network. Global COVID Vaccine Safety (GCoVS). Auckland (NZ): Global Vaccine Data Network; 2022 [accessed 2023 October 13]. Available from: https:\/\/www.globalvaccinedatanetwork.org\/global-covid-vaccine-safety-gcovs."},{"key":"10.1016\/j.vaccine.2024.01.100_b0055","unstructured":"Global Vaccine Data Network. Auckland (NZ): Global Vaccine Data Network; 2023 [accessed 2023 October 13]. Available from: https:\/\/www.globalvaccinedatanetwork.org\/."},{"key":"10.1016\/j.vaccine.2024.01.100_b0060","unstructured":"Global Vaccine Data Network. GVDN: Observed vs expected (OE) dashboard. Auckland (NZ): Global Vaccine Data Network; 2023 [updated 2023 December 8; cited 2023 December 13]. Available from: www.globalvaccinedatanetwork.org\/Data-Dashboards."},{"key":"10.1016\/j.vaccine.2024.01.100_b0065","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational Global Vaccine Data Network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.100_b0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8879","article-title":"Incidence of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the vaccine safety datalink","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.01.100_b0075","unstructured":"World Health Organization. Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines n.d. https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs (accessed October 23, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0080","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.vaccine.2024.01.100_b0085","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield). Accessed October 23, 2023. https:\/\/www.who.int\/news\/item\/16-04-2021-global-advisory-committee-on-vaccine-safety-(gacvs)-review-of-latest-evidence-of-rare-adverse-blood-coagulation-events-with-astrazeneca-covid-19-vaccine-(vaxzevria-and-covishield)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/pds.5419","article-title":"Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 38.6 million people in six European countries","volume":"31","author":"Burn","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.100_b0095","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.100_b0100","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/M21-2452","article-title":"Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study","volume":"175","author":"Hviid","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2024.01.100_b0105","unstructured":"World Health Organization. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS): updated guidance regarding myocarditis and pericarditis reported with COVID-19 mRNA vaccines. Accessed October 23, 2023. https:\/\/www.who.int\/news\/item\/09-07-2021-gacvs-guidance-myocarditis-pericarditis-covid-19-mrna-vaccines."},{"key":"10.1016\/j.vaccine.2024.01.100_b0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamacardio.2022.0583","article-title":"SARS-CoV-2 vaccination and myocarditis in a Nordic cohort study of 23 million residents","volume":"7","author":"Karlstad","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vaccine.2024.01.100_b0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices \u2014 United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.01.100_b0120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40261-022-01164-4","article-title":"Guillain-Barr\u00e9 syndrome associated with COVID-19 vaccines: a perspective from spontaneous report data","volume":"42","author":"Atzenhoffer","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.vaccine.2024.01.100_b0125","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14740338.2022.2120607","article-title":"Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom","volume":"22","author":"Otero-Losada","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.vaccine.2024.01.100_b0130","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1016\/j.vaccine.2022.06.010","article-title":"Safety of COVID-19 vaccination and acute neurological events: a self-controlled case series in England using the OpenSAFELY platform","volume":"40","author":"Walker","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.100_b0135","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.01.100_b0140","first-page":"376","article-title":"Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2024.01.100_b0145","unstructured":"European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca) | European Medicines Agency. Accessed October 26, 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria#product-information-section."},{"key":"10.1016\/j.vaccine.2024.01.100_b0150","unstructured":"COVID-19 vaccine weekly safety report - 09-12-2021 | Therapeutic Goods Administration (TGA). Accessed December 5, 2023. https:\/\/www.tga.gov.au\/news\/covid-19-vaccine-safety-reports\/covid-19-vaccine-weekly-safety-report-09-12-2021#section-1298."},{"key":"10.1016\/j.vaccine.2024.01.100_b0155","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.26172","article-title":"COVID-19 vaccine-associated cerebral venous thrombosis in Germany","volume":"90","author":"Schulz","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.vaccine.2024.01.100_b0160","doi-asserted-by":"crossref","unstructured":"Andrews NJ, Stowe J, Ramsay ME, Miller E. Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: a national cohort study in England. Lancet Reg Heal Eur 2022;13. doi: 10.1016\/J.LANEPE.2021.100260.","DOI":"10.1016\/j.lanepe.2021.100260"},{"key":"10.1016\/j.vaccine.2024.01.100_b0165","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1016\/j.vaccine.2021.10.030","article-title":"Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria","volume":"39","author":"Gordon","year":"2021","journal-title":"Australia Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.100_b0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18505","article-title":"Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.01.100_b0175","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1503\/cmaj.220676","article-title":"Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study","volume":"194","author":"Naveed","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2024.01.100_b0180","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1016\/j.jacc.2022.08.799","article-title":"Comparative risk of myocarditis\/pericarditis following second doses of BNT162b2 and mRNA-1273 coronavirus vaccines","volume":"80","author":"Naveed","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vaccine.2024.01.100_b0185","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2024.01.100_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065687","article-title":"Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis","volume":"13","author":"Alami","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.01.100_b0195","unstructured":"COVID-19 vaccine safety report - 13-07-2023 | Therapeutic Goods Administration (TGA) n.d. https:\/\/www.tga.gov.au\/news\/covid-19-vaccine-safety-reports\/covid-19-vaccine-safety-report-13-07-2023#myocarditis-and-pericarditis-after-covid19-vaccination (accessed December 5, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0200","unstructured":"Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC n.d. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/myocarditis.html (accessed December 5, 2023)."},{"key":"10.1016\/j.vaccine.2024.01.100_b0205","article-title":"Acute disseminated encephalomyelitis (ADEM)-like illness in a pediatric patient following COVID-19 vaccination","volume":"9","author":"Brock","year":"2023","journal-title":"BJR | Case Rep"},{"key":"10.1016\/j.vaccine.2024.01.100_b0210","article-title":"Fatal acute disseminated encephalomyelitis post-COVID-19 vaccination: a rare case report","volume":"14","author":"Nimkar","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.vaccine.2024.01.100_b0215","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12024-021-00440-7","article-title":"Acute disseminated encephalomyelitis (ADEM) following recent Oxford\/AstraZeneca COVID-19 vaccination","volume":"18","author":"Permezel","year":"2022","journal-title":"Forensic Sci Med Pathol"},{"key":"10.1016\/j.vaccine.2024.01.100_b0220","article-title":"Post Moderna Vaccine associated acute disseminated encephalomyelitis (ADEM) - a case report","volume":"17","author":"Khan","year":"2022","journal-title":"Pak J Neurol Sci"},{"key":"10.1016\/j.vaccine.2024.01.100_b0225","unstructured":"European Medicines Agency. COVID-19 Vaccine Safety Update.; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-18-june-2021_en.pdf."},{"key":"10.1016\/j.vaccine.2024.01.100_b0230","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ana.26339","article-title":"Neurological events reported after COVID-19 vaccines: an analysis of vaccine adverse event reporting system","volume":"91","author":"Frontera","year":"2022","journal-title":"Ann Neurol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24001270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T06:19:26Z","timestamp":1729145966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24001270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0264410X24001270"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}